A therapeutic use of the methadone fluvoxamine drug interaction

Journal of Addictive Diseases

Volumn 18, Issue 4, 1999, Pages 5-12

  Demaria, Peter A ^a   Serota, Ronald D ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Diazepam; Fluvoxamine; Methadone; Methadone maintenance; Opiate dependence; Therapeutic drug monitoring

Indexed keywords

CANNABIS; COCAINE; DIAMORPHINE; DIAZEPAM; FLUVOXAMINE; METHADONE; OXYCODONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY NEUROSIS; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG MONITORING; FEMALE; HUMAN; METHADONE TREATMENT; OPIATE ADDICTION; WITHDRAWAL SYNDROME;

ADULT; DRUG INTERACTIONS; FEMALE; FLUVOXAMINE; HUMANS; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0342979783     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v18n04_02     Document Type: Article

References (33)

1. Dole V, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965; 193: 646-650.
2. Zweben J, Payte JT. Methadone maintenance in the treatment of opioid dependence: a current perspective. In Addiction Medicine (special issue) West J Med. 1990 (May); 152: 588-599.
3. Cooper JR. Ineffective use of psychoactive drugs: methadone treatment is no exception. JAMA. 1992; 267: 281-282.
4. D’Aunno T, Vaughn TE. Variations in methadone treatment practices: results from a national study. JAMA. 1992; 267: 253-258.
5. United States General Accounting Office. Methadone maintenance: some treatment programs are not effective: greater federal oversight necessary. General Accounting Office, Washington, DC, 1990. 291 CFR 505 (d), (6), i, C. Pennsylvania Methadone Regulations, 716.6 (a).
6. Ball J, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag, 1991.
7. Caplehorn J, Bell J. Methadone dosage and retention ofpatients in methadone maintenance treatment. Med J of Australia. 1991; 154: 195-199.
8. Payte JT, Khuri E. Principles of methadone dose determination, Chapter 5 In Parrino, M. (ed.), State Methadone Guidelines, TIP series, #1, U.S. Department of Health and Human Services, Center for Substance Abuse Treatment, Rockville, MD, 1993.
9. Horns WH, Rado M, Goldstein A. Plasma levels and symptoms complaints in patients maintained on daily dosage of methadone hydrochloride. Clin Pharmacol Ther. 1975; 17(6): 636-649.
10. Borg L, Ho A, Peters J, Kreek MJ. Availability of reliable serum methadone determinations for management of symptomatic patients. J Add Dis. 1995; 14(3): 83-96.
11. Holmstrand J, Anggard E, Gunne L. Methadone maintenance: plasma levels and therapeutic outcome. Clin Pharmacol Ther. 1978; 23(2): 175-180.
12. Bell J, Seres V, Bowron P, et al. The use of serum methadone levels in patients receiving methadone maintenance. Clin Pharmacol Ther. 1988; 43: 623-629.
13. Dole V. Implications of methadone maintenance for theories of narcotic addiction. JAMA. 1988; 260: 3025-3029.
14. Kreek MJ. Plasma and urine levels of methadone. NY State J of Med. 1973; 73(23): 2773-2777.
15. Wolff K, Sanderson M, Hay AWM, Ralstrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clinical Chemistry. 1991; 37(2):205-209.
16. Loimer N, Schmid R. The use of plasma levels to optimize methadone maintenance treatment. Drug and Alcohol Dependence. 1992; 30: 241-246.
17. Loimer N, Schmid R, Grunberger J, Jagsch R, et al. Psychophysiologic reactions in methadone maintenance patients do not correlate with methadone plasma levels. Psychopharmacology. 1991; 103: 538-540.
18. Kreek MJ. Medical management of methadone maintained patients. In: Low- inson, JH and Ruiz, P. (eds.) Substance abuse: Clinical problems and perspectives, Williams and Wilkins, Baltimore, 1981, pp. 660-670.
19. Nilsson MI, Widerlov E, Meresaar U, Angaard E. Effect of urinary pH on the disposition of methadone in man. Eur. J. of Clin. Pharm. 1982: 22; 337-342.
20. Tong TG, Pond SM, Kreek MJ, et al. Phenytoin-induced methadone withdrawal. Ann IntMed. 1981: 94; 349-351.
21. Holmes V. Rifampin induced methadone withdrawal in AIDS. (letter), J. Clin Psychopharm. 1990: 10(6); 443-444.
22. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin induced methadone withdrawal. NEJM. 1976: 294(20); 1104-1106.
23. Saxon AJ, Whitaker S, Hawker CS. Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: two cases. J Clin Psych. 1989: 50; 228-229.
24. Kuhn KL, Halikas JA, Kemp KD. Carbamazepine treatment of cocaine dependence in methadone maintenance patents with dual opiate-cocaine dependence. In: Harris, LS (ed), Problems of drug dependence, NIDA Research Monograph 95, NIDA, Rockville, MD, 1989.
25. Alvares AP, Kappas A. Influence of phenobarbital on the metabolism and analgesic effect of methadone in rats. J Lab Clin Med. 1972: 79; 439-451.
26. Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monitoring. 1994: 16; 42-45.
27. Hobbs WR, Rall TW, Verdoorn TA. Hypnotics and sedatives: Ethanol. In: Hardman JG, Limbird LF, ed. Goodman & Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996, pp. 361-396.
28. von Bahr C, Steiner E, Koike Y, Gabrielsson J. Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism. Clin Pharmacol Ther. 1998; 64: 18-26.
29. Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in the 66-hydroxycortisol urinary excretion in humans-a putative measure of CYP3A induction. J of Pharmaceutical Sciences 1995: 84(3); 292-294.
30. Bertilsson L, Tomson T, Tybring C. Pharmacokinetics: time dependant changes-autoinduction of carbamazepine epoxidation. J Clin Pharmacol. 1986: 26; 459-462.
31. Perucca E, Gatti G, Spina, E. Clinical pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics. 1994: 27(3); 175-190.
32. Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology. 1997: 117;13-23.
33. Perucca E, Gatti G, Cipolla G, Spina E, et al. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clin Pharmacol Ther. 1994: 56(5); 471-476.